Loading clinical trials...
Loading clinical trials...
Non-Interventional Study Investigating the Use of Golimumab (Simponi®) in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
This is a study to assess the use of golimumab (Simponi®) in participants with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The study objective is to evaluate the clinical safety of golimumab (Simponi®) under real-life, clinical practice conditions as assessed by the incidence and type of (serious) adverse events and changes in clinical status of participants as assessed by clinical parameters.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Start Date
April 1, 2010
Primary Completion Date
September 1, 2015
Completion Date
September 1, 2015
Last Updated
November 1, 2016
1,613
ACTUAL participants
Simponi®
DRUG
Methotrexate
DRUG
Lead Sponsor
Merck Sharp & Dohme LLC
NCT01422694
NCT07017686
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06522035